Oral dimethyl fumarate (BG-12) is in development for the treatment of relapsing multiple sclerosis (MS), though experimental evidence already suggests it may provide anti-inflammatory and cytoprotective effects by activating the transcription factor Nrf2.
While phenotypes of multiple sclerosis (MS) are well-established, there remains heterogeneity among patients that fit existing clinical definitions.
Compared with placebo, teriflunomide was shown to significantly reduce the occurrence of relapses with sequelae and relapses treated with corticosteroids in a post-hoc analysis of pivotal clinical trial data.
Data presented at the 2013 AAN Annual Meeting indicate that MAP0004, which delivers dihydroergotamine (DHE) via oral inhalation, is effective in the acute treatment of severe migraine pain.
Study results show a novel formulation of oxcarbazepine may provide long-term seizure reduction in patients with refractory epilepsy, while a separate trial produced promising results for long-term lacosamide treatment in elderly patients with partial-onset seizures.
Severe neuropathic pain due to diabetic peripheral neuropathy is associated with negative health impact and increased healthcare utilization, underscoring the need for the development of safe and effective treatments.
Ability to differentiate between subtypes of frontotemporal lobar degeneration could accelerate research into the pathology and prevention of this disease and aid in the design of disease-modifying therapies.
MRI studies show comorbid depression and fatigue may have an effect on gray matter atrophy in specific regions of the brain in patients with multiple sclerosis.
Results from the multicenter SET study suggest that smoking, response to Epstein Barr virus, and other environmental factors contribute to disease progression in multiple sclerosis.
Better understanding of the processes of cortical rewiring and recruitment will enable researchers to develop more effective treatments for multiple sclerosis.
Patients with Parkinson’s disease and neurogenic orthostatic hypotension treated with droxidopa showed improvements in symptoms of dizziness and lightheadedness, and in systolic blood pressure.
Study shows levetiracetam, carbamazepine, and topiramate are equally safe and effective in the treatment of adult patients with epilepsy induced by MELAS. However, valproate was found to be less effective and associated with more adverse events.
Researchers report the monoclonal antibody solanezumab may improve cognition and activities of daily living for patients with mild Alzheimer’s disease.
Study results suggest that oxidative stress may play a direct role in the neurodegeneration that occurs in ALS.
More than 90% of participants in the Therapy Optimization in Multiple Sclerosis (TOP MS) study were still on their original disease modifying therapy at one year follow-up.
Electronic data can be used to create “virtual cohorts” to rapidly implement studies of MS disease activity, comorbidities, pharmacogenomics, and presymptomatic disease.
MRI data shows that multiple sclerosis patients with central neuropathic pain often have lesions focused in the center of the mid-thoracic spinal cord.
Study results show that intrathecal ziconotide provides significant pain relief for patients with refractory painful myelopathies and neuropathies.
Researchers successfully treated a patient with refractory complex regional pain syndrome by inducing a coma with ketamine and dexmedetomidine.
DaTscan™ SPECT imaging can help physicians assess diagnostic category and improve diagnostic confidence for patients with dementia with Lewy bodies.
In the Multiple Sclerosis Treatment Safety poster session at the American Academy of Neurology (AAN) 2013 Annual Meeting, Paul O’Connor, of St. Michael's Hospital, in Toronto, and his colleagues presented a study designed to determine whether immune responses to seasonal influenza vaccination are preserved in teriflunomide-treated patients with relapsing forms of multiple sclerosis (RMS).
In the Multiple Sclerosis Treatment Safety poster session at the American Academy of Neurology (AAN) 2013 Annual Meeting, Barry Singer, a neurologist at the Missouri Baptist Medical Center, in St. Louis, and founder and director of the MS Center for Innovations in Care, and his co-authors presented an analysis of infection rates in three placebo-controlled teriflunomide studies.
Fernando Figueira, MD, and his associates from the Hospital São Francisco, in Rio De Janeiro, Brazil, called for expanded requirements for "disease-free" designation in multiple sclerosis (MS) patients in a Multiple Sclerosis Treatment poster session at the American Academy of Neurology (AAN) 2013 Annual Meeting.
Study results show that IPX066 demonstrated a favorable tolerability profile throughout extended dosing in early Parkinson’s disease (PD) and during the long-term management of patients with advanced PD.
Three new treatments show promise for patients with Parkinson's disease, according to three studies presented at the annual meeting of the American Academy of Neurology.
In a first report of human trials, a selective alpha-2C adrenoceptor antagonist improves memory in patients with Alzheimer's disease (AD), according to a study presented at the annual meeting of the American Academy of Neurology.
Study results suggest that age and timing of treatment initiation with interferon beta therapy may play a larger role than relapse in long-term disability in patients with multiple sclerosis.
Disease activity, patient preference, and other factors should be considered when selecting DMT for the treatment of multiple sclerosis.
Seminar at the American Academy of Neurology annual meeting discusses the systematic approach to diagnosing patients with MS, initial medication selection, and changing treatments.
Switching from oral administration of the non-ergoline dopamine agonist, rotigotine, to a transdermal delivery system may improve gastrointestinal symptoms for patients with Parkinson's disease.
Updated guideline recommends athletes with suspected concussion "be immediately taken out of the game and not returned until assessed by a licensed health care professional trained in concussion, return to play slowly and only after all acute symptoms are gone."
In the MOTION and SETTLE studies, safinamide was shown to be effective in the treatment of patients with Parkinson's disease as add-on therapy to a stable dose of a single dopamine agonist and as add-on therapy for patients taking levodopa.
News and updates about AAN 2013, the 65th Annual Meeting of the American Academy of Neurology.
